RxDoctor Payments Data

William Courson, DO

Family Medicine · Newnan, GANPI 1720427388

Payments from drug & device makers

$7,959in general payments, 2019–2025

Across 426 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$850
  • Novo Nordisk$771
  • Lilly USA, LLC$556
  • Pfizer$547
  • Johnson & Johnson$512
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$7,959100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,959 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$91,392
Medicare patients
305
Services billed
1,490

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin111$157,989
MounjaroTirzepatide103$157,472
OzempicSemaglutide63$86,312
EliquisApixaban69$72,661
TrulicityDulaglutide20$35,721
RexultiBrexpiprazole11$31,365
JanuviaSitagliptin Phosphate20$29,338
GemtesaVibegron35$26,965
SynjardyEmpagliflozin/Metformin Hcl12$21,217
FarxigaDapagliflozin Propanediol13$17,198
Repatha SureclickEvolocumab13$15,110
MyrbetriqMirabegron13$10,596
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$8,241
Atorvastatin Calcium740$6,427
NexiumEsomeprazole Magnesium12$5,600

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$556$193,193123 claims
Boehringer IngelheimJardiance, Synjardy$484$179,206123 claims
Novo NordiskOzempic$771$86,31263 claims
PfizerEliquis$547$72,66169 claims
Otsuka America Pharmaceutical, Inc.Rexulti$251$31,36511 claims
MerckJanuvia$21$29,33820 claims
Sumitomo Pharma America, Inc.Gemtesa$97$26,96535 claims
AstraZenecaFarxiga, Nexium$850$22,79825 claims
GSKTrelegy Ellipta, Shingrix$235$11,88128 claims
Astellas Pharma US IncMyrbetriq$266$10,59613 claims
AbbVieSynthroid$1,056$2,45832 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Newnan

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →